How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

691 results for

Dysuria in Children

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Tepadina - thiotepa

(Gutierrez-Delgado, 2003; Gutierrez-Delgado, 2001) makes high dose thiotepa one of the first drugs used in this context in pre-irradiated or very young children. A broad base of clinical experience with thiotepa and different combination partners in multiple complex contexts is available. Thiotepa can certainly be regarded as well established and systematically used in the dose-intensive treatment of paediatric brain tumours. Thiotepa is covering all patient ages, from pediatric to elderly, giving (...) for the following indication: conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult and paediatric patients. The legal basis for this application refers to: Article 10(a) of Directive 2001/83/EC, as amended - Well-established use application. Information on Paediatric requirements Not applicable Information relating to Orphan Market Exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847

2010 European Medicines Agency - EPARs

262. PecFent - fentanyl

maintenance opioid therapy are those who are taking at le morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 ast 60 mg of oral mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week al basis for this application refers to: r hybrid medicinal omplete administrative information, complete quality data, and appropriate non-clinical and clinical data for a hybrid medicinal product. on Paediatric requirements (...) to EU GMP and relate the marketing application for the manufacture of PecFent nasal spray has manufacturing site can be considered acceptable for the manufacture of PecFent with EU GMP. PecFent is presented in a 5.3 ml capacity, Ph. Eur. Type I glass bottle sealed w closure, metered-dose nasal spray pu actuation is designed to deliver 100 µl of solution containing 100 µg or 400 µg fenta the pump will deliver eight sprays before it locks. The assembled unit will be placed in a child-resistant outer

2010 European Medicines Agency - EPARs

263. Milnacipran Pierre Fabre Medicament

studies have not been performed. The use of milnacipran in children is therefore not supported by any juvenile toxicity studies. • Toxicokinetic data Toxicokinetic data for milnacipran racemate are available for all animal species investigated. Toxicokinetic studies differentiating between the single enantiomers have only been performed for the rat. Milnacipran did not accumulate following repeated oral administration in animal species investigated. No clear gender effect was observed in nonclinical

2010 European Medicines Agency - EPARs

264. Impulsor - milnacipran

fertility of F 1 females. The results of the pre-/postnatal development studies did not yield a clear indication as to whether reduced pup viability was directly due to treatment or was just secondary to impaired maternal care during lactation. Juvenile toxicity studies have not been performed. The use of milnacipran in children is therefore not supported by any juvenile toxicity studies. • Toxicokinetic data Toxicokinetic data for milnacipran racemate are available for all animal species investigated

2010 European Medicines Agency - EPARs

265. A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)

the study. Exclusion Criteria: Patients with difficulty urinating have a PVR of 50 ml or more. Patients requiring indwelling catheter or clean intermittent catheterization (CIC). Female patients who is pregnant, lactating, or with child-bearing potential without contraception. People who are allergic to study drugs or its ingredients or allergic should be excluded. Current severe cardiovascular disease ongoing clinical instability. Renal insufficiency and serum creatinine greater than 1.5 times (...) the upper limit of normal. Liver diseases, ALT or AST greater than 2 times the upper limit of normal. Alcohol or drug abusers. Have participated in the clinical trials of other drugs within a month. Any previous botulinum toxin therapy for a urologic condition within 6 months. Urinary tract infection (① patients with symptoms of fever, pyuria, urinary frequency, urgency or dysuria etc.; ② positive urine culture ( bacterial colony counts > 10^5 cfu/ml) or urine WBC> 10/ HPF; meet both of ① and ② or any

2016 Clinical Trials

266. Benefits of Peri-surgical Physical Therapy in the Management of III and IV Grades of Pelvic Organ Prolapse

, incontinence, coital incontinence, nocturnal enuresis, frequency of urinary tract infections, dysuria and urinary difficulty). [ Time Frame: up to 24th months post-surgery. ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using (...) the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Consecutive women diagnosed with grade III and IV pelvic organ prolapse, which would be operated for this reason at the Asturias Prince Hospital (Madrid-Spain). Exclusion Criteria: Women diagnosed with different III / IV grade of POP or a history of conservative treatment

2016 Clinical Trials

267. Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)

: Fondation Ildys Collaborators: Vaincre la Mucoviscidose University Hospital, Brest Information provided by (Responsible Party): Fondation Ildys Study Details Study Description Go to Brief Summary: This observational study evaluates prevalence of functional perinea disorders (stress urinary incontinence, overactive bladder syndrome, dysuria, anal incontinence) on CF adults patients of the North-West CF Network. Its aims are to measure the severity of urinary and anorectal symptoms ; assess their impact (...) ] Assesses lower urinary tract symptoms (stress urinary incontinence, overactive bladder syndrome and dysuria) Secondary Outcome Measures : Wexner Fecal Incontinence Scale [ Time Frame: at time of inclusion ] Assesses anal incontinence and its impact on quality of life SF-Qualiveen questionnaire [ Time Frame: at time of inclusion ] Assesses impact of urinary disorders on quality of life Cystic Fibrosis Questionnaire-Revised (CFQ-R) [ Time Frame: at time of inclusion ] Assesses quality of live related

2016 Clinical Trials

268. Composite Paraganglioma and Neuroblastoma of the Urinary Bladder: A Rare Histopathological Entity Full Text available with Trip Pro

Composite Paraganglioma and Neuroblastoma of the Urinary Bladder: A Rare Histopathological Entity Paraganglioma of the urinary bladder is an uncommon clinical entity. Neuroblastoma of the urinary bladder is another rare tumor with only 7 reported cases, all in children. This report presents the case of a composite paraganglioma and neuroblastoma in a 45 year-old male who presented with dysuria and flank pain. On the computerized tomography scan, the bladder wall overlying the tumor was smooth

2015 Current urology

269. Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

employee, or is in a dependant relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress. Is taking any combination of dual renin-angiotensin system (RAS) inhibition (such as an ACE inhibitor and an ARB or an ACE inhibitor and a mineralocorticoid receptor antagonist). Has type 1 diabetes mellitus or a history of ketoacidosis. Has poorly-controlled blood pressure (systolic blood pressure >160 or diastolic blood (...) transplant. Has hypersensitivity to other monoclonal antibodies (mAb) or to any component of the formulation of MLN1202. Has history of malignancy within the previous 5 years (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin). Is symptomatic with dysuria, and has a positive urine culture at screening. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending

2015 Clinical Trials

270. The prostatic utricle cyst with huge calculus and hypospadias: A case report and a review of the literature Full Text available with Trip Pro

The prostatic utricle cyst with huge calculus and hypospadias: A case report and a review of the literature Prostatic utricle cysts with calculus and hypospadias are rare. There are a few reported cases. We present a case of a prostatic utricle cyst with huge calculus in a 25-year-old male. He had a history of left cryptorchidism and surgery for penoscrotal hypospadias in his infancy. He was referred for frequent micturition, urgency of urination, urine pain, terminal hematuria, and dysuria

2015 Canadian Urological Association Journal

271. Labial adhesion and bacteriuria Full Text available with Trip Pro

Labial adhesion and bacteriuria The purpose of this study is to evaluate the clinical presentation, laboratory findings, and response to treatment in girls with labial adhesion younger than 23 months.A retrospective chart review of all girls younger than 23 months with the diagnosis of labial adhesion was referred to Dr Sheikh children's clinic in Mashhad in northeast Iran between 1998 and 2013.Sixty-three patients were diagnosed with labial adhesion during the review period. Most patients were (...) diagnosed by physicians during the physical examination or during the evaluation for their voiding problems. The most prevalent symptom among patients was dysuria and restlessness while voiding. Twenty-one (33.3%) patients had a history of urinary tract infection. 17 (26.9%) patients had sterile pyuria and 69.8% showed presence of bacteria in their urine samples.Physicians may frequently encounter pre-pubertal girls whose urinalysis may show sterile pyuria or presence of bacteria with colony counts <105

2015 Journal of the Turkish German Gynecological Association

272. Urethral Calculi in a 7-Year-old Boy Presenting as a Large Scrotal Mass After Surgery of Exstrophy-epispadias Repair. (Abstract)

Urethral Calculi in a 7-Year-old Boy Presenting as a Large Scrotal Mass After Surgery of Exstrophy-epispadias Repair. Urethral calculi are extremely rare in pediatric population and are usually presented with dysuria, hematuria, lower urinary tract obstruction, and rarely as a scrotal mass. We here report a giant primary urethral stone presenting as a scrotal mass that developed in the penile urethra resulting from a postsurgical complication of exstrophy-epispadias repair. A 7-year-old boy (...) was admitted with the complaint of scrotal mass and dysuria. Computerized tomography confirmed giant urethral stone impacted to diverticulum of urethra. Cystoscopy revealed a nonobstructed stone in the urethra related to a posterior diverticulum. After scrotal incision, stone was removed with open diverticulectomy. Copyright © 2015 Elsevier Inc. All rights reserved.

2015 Urology

273. Menarche? A Case of Abdominal Pain and Vaginal Bleeding in a Preadolescent Girl. (Abstract)

Menarche? A Case of Abdominal Pain and Vaginal Bleeding in a Preadolescent Girl. Abdominal pain is one of the most common complaints in the pediatric ED. Because of the broad range of potential diagnoses, it can pose challenges in diagnosis and therapy in the preadolescent girl. An 11-year-old previously healthy girl presented to our pediatric ED with fever, decreased appetite, vaginal bleeding, and abdominal pain. Initial evaluation yielded elevated creatinine levels, leukocytosis (...) present as vaginal discharge, vaginal bleeding, abdominal pain, dysuria, or hematuria. Because symptoms can be diverse, an intravaginal or uterine foreign body should be considered in the preteen female patient presenting to the ED with abdominal pain.Copyright © 2015 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

2015 Annals of Emergency Medicine

274. Safety and Tolerability of Metronidazole Gel 1.3%

] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 12 Years to 17 Years (Child) Sexes Eligible for Study: Female (...) infectious causes of vulvovaginal infection or condition that in the Investigator's opinion would confound the interpretation of the study results. Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal area. Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies (non-intravaginal) are acceptable. Has taken disulfiram or systemic corticosteroids (oral or injected) within 14 days

2015 Clinical Trials

275. Bladder Cancer

been associated with an increased risk of bladder cancer. Chronic urinary tract infections and infection with the parasite S. haematobium have also been associated with an increased risk of bladder cancer, often squamous cell carcinomas. Chronic inflammation is thought to play a key role in carcinogenesis in these settings. Clinical Features Bladder cancer typically presents with gross or microscopic hematuria. Less commonly, patients may complain of urinary frequency, nocturia, and dysuria

2012 PDQ - NCI's Comprehensive Cancer Database

276. Runners with red pee = red alert?…The answer to MOOC’s question of the week

, physical and investigations: Renal or ureteric stone will cause pain. The condition is uncommon in young athletes, but the first episode can occur in youth. A detailed metabolic work up is required if this condition is diagnosed. Foot strike haemolysis with haemaglobin pigment causing red urine. This is common when old or worn shoes are used, and the running occurs on a concrete surface. Urinary tract infections classically presents with dysuria and frequency rather than severe abdominal pain (...) Consensus statement 20 March 2019 | Theme: UnderStrap Child British Journal of Sports Medicine by . (Version: 0.1.5)

2016 British Journal of Sports Medicine Blog

277. Research and Reviews in the Fastlane 135 Full Text available with Trip Pro

and pericardial effusion in children: contemporary epidemiology and management. J Am Heart Assoc. 2014. PMID: Pediatric Chest Pain is common… and fortunately, often due to benign causes. Before you announce that this is merely costochondritis, be sure to contemplate Pericarditis. Recommended by: Sean Fox The R&R iconoclastic sneak peek icon key R&R Hall of famer You simply MUST READ this! R&R Hot stuff! Everyone’s going to be talking about this R&R Landmark paper A paper that made a difference R&R Game (...) % of ED patients with headaches got opioids (which, incidentally, don’t work for headache). We need to do better. Recommended by: Seth Trueger Emergency Medicine Gágyor I, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ (Clinical research ed.) . 2015. PMID: Despite being one of the greatest advances in modern medicine, antibiotics get a bad rap in EBM. Do they work in UTI? Probably, as this RCT shows lower rates of dysuria

2016 Life in the Fast Lane Blog

279. Fampridine Sustained Release (4-aminopyridine)

data from healthy subjects and from those with various diseases as MS, SCI, and renal impairment. No pediatric patients were included in the efficacy database. Despite age limits for trials as low as 18 years, the youngest age enrolled was 24 years. The overall clinical report is a joint review with input from efficacy, safety, and biometrics reviewers. All the reviewers are jointly responsible for the synthesis and documentation of the overall conclusions for the application review. 5.2 Review (...) in September 2005. Also, the trial enrolled 304 subjects instead of the planned 240. Protocol: Summary of inclusion criteria: Subjects with clinically definite MS, aged 18 to 70 years, able to perform two trials of Timed 25 foot Walk within 8-45 seconds at the screening visit. Summary of exclusion criteria: Female who is either pregnant or breastfeeding, and female of child-bearing potential not on birth control measures; history of seizures or evidence of epileptiform activity on EEG; known allergy

2009 FDA - Drug Approval Package

280. Rilutek - riluzole

drug. Special Populations Hepatic Impairment: The area-under-the-curve (AUC) of riluzole, after a single 50 mg oral dose, increases by about 1.7-fold in patients with mild chronic liver insufficiency (n=6; Child-Pugh’s score A) and by about 3-fold in patients with moderate chronic liver insufficiency (n=6; Child-Pugh’s score B) compared to healthy volunteers (n=12) (see WARNINGS and PRECAUTIONS). The pharmacokinetics of riluzole have not been studied in patients with severe hepatic impairment. Page (...) light. RILUTEK must be kept out of the reach of children. Laboratory Tests Serum aminotransferases including ALT levels should be measured before and during riluzole therapy. Serum ALT levels should be evaluated every month during the first 3 months of treatment, every 3 months during the remainder of the first year, and periodically thereafter. Page 6 Serum ALT levels should be evaluated more frequently in patients who develop elevations (see WARNINGS). As noted in the WARNINGS Section

2009 FDA - Drug Approval Package

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>